Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

435 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effectiveness, safety, and patient-reported outcomes of bictegravir/emtricitabine/tenofovir alafenamide in routine clinical care in Italy: 12-Month results from the BICSTaR cohort.
Antinori A, Marchetti G, Esposito V, Rusconi S, Canetti D, Quiros-Roldan E, Candelaresi B, Saracino A, Andreoni M, Marongiu A, Cassidy T, Thorpe D, Albini L, Caldera R, Forcina G, Di Perri G. Antinori A, et al. Among authors: rusconi s. Int J STD AIDS. 2025 Jan 8:9564624241308372. doi: 10.1177/09564624241308372. Online ahead of print. Int J STD AIDS. 2025. PMID: 39772928 Free article.
First-line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison.
Taramasso L, Di Biagio A, Maggiolo F, Tavelli A, Lo Caputo S, Bonora S, Zaccarelli M, Caramello P, Costantini A, Viscoli C, d'Arminio Monforte A, Cozzi-Lepri A; Italian Cohort Naive Antiretrovirals (ICONA) Foundation Study Group. Taramasso L, et al. HIV Med. 2018 May 30. doi: 10.1111/hiv.12628. Online ahead of print. HIV Med. 2018. PMID: 29846042 Free article.
Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy.
Saracino A, Zaccarelli M, Lorenzini P, Bandera A, Marchetti G, Castelli F, Gori A, Girardi E, Mussini C, Bonfanti P, Ammassari A, d'Arminio Monforte A; Icona Foundation Study Group. Saracino A, et al. BMC Public Health. 2018 Jul 13;18(1):870. doi: 10.1186/s12889-018-5804-z. BMC Public Health. 2018. PMID: 30005709 Free PMC article.
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART.
Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group. Ceccherini-Silberstein F, et al. J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350. J Antimicrob Chemother. 2018. PMID: 30247724 Free article.
Incidence and factors associated with the risk of sexually transmitted diseases in HIV-infected people seen for care in Italy: data from the Icona Foundation cohort.
Cingolani A, Zona S, Girardi E, Cozzi-Lepri A, Monno L, Quiros Roldan E, Guaraldi G, Antinori A, D'Arminio Monforte A, Marcotullio S; Community-Oriented Study Group of the Icona Foundation Study Group. Cingolani A, et al. HIV Med. 2015 Aug;16(7):412-20. doi: 10.1111/hiv.12226. Epub 2015 May 11. HIV Med. 2015. PMID: 25959419 Free PMC article.
Evolution of major non-HIV-related comorbidities in HIV-infected patients in the Italian Cohort of Individuals, Naïve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004-2014.
d'Arminio Monforte A, Diaz-Cuervo H, De Luca A, Maggiolo F, Cingolani A, Bonora S, Castagna A, Girardi E, Antinori A, Lo Caputo S, Guaraldi G, Cozzi-Lepri A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. HIV Med. 2019 Feb;20(2):99-109. doi: 10.1111/hiv.12683. Epub 2018 Nov 21. HIV Med. 2019. PMID: 30461158 Free article.
Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus.
Mussini C, Lorenzini P, Puoti M, Lichtner M, Lapadula G, Di Giambenedetto S, Antinori A, Madeddu G, Cozzi-Lepri A, d'Arminio Monforte A, De Luca A; ICONA Foundation Study Group. Mussini C, et al. PLoS One. 2015 Dec 7;10(12):e0140877. doi: 10.1371/journal.pone.0140877. eCollection 2015. PLoS One. 2015. PMID: 26640953 Free PMC article.
Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?
Shanyinde M, Girardi E, Puoti M, De Luca A, Sighinolfi L, Caterina UF, Caramello P, Lampe FC, D'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group. Shanyinde M, et al. BMC Public Health. 2019 Oct 15;19(1):1291. doi: 10.1186/s12889-019-7608-1. BMC Public Health. 2019. PMID: 31615542 Free PMC article.
435 results